Last updated: October 23, 2026
SYNRIBO, the brand name for omacetaxine mepesuccinate, is a niche hematology drug approved for adults with chronic-phase or accelerated-phase chronic myeloid leukemia (CML) who are resistant or intolerant to at least two tyrosine kinase inhibitors (TKIs). The product obtained U.S. accelerated approval in 2012, but its commercial opportunity remained limited by a small treatment population, intensive subcutaneous dosing, competing TKIs, and the absence of publicly reported standalone sales.
The product’s economic profile is best characterized as a low-volume, specialty-oncology asset rather than a major growth driver for Teva Pharmaceutical Industries. Public filings do not identify SYNRIBO revenue separately. Its financial trajectory appears to have been shaped more by declining clinical relevance and portfolio rationalization than by patent expiry or generic competition.
What is SYNRIBO and how does omacetaxine work?
SYNRIBO contains omacetaxine mepesuccinate, a subcutaneously administered inhibitor of protein synthesis. It is used in adults with chronic-phase CML or accelerated-phase CML who have resistance or intolerance to two or more TKIs.
Unlike BCR-ABL TKIs such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, omacetaxine does not depend on direct inhibition of the BCR-ABL kinase domain. Its differentiated mechanism created a potential treatment option for patients with resistance involving kinase-domain mutations, including some patients for whom multiple TKIs had failed.
| Attribute |
SYNRIBO |
| Active ingredient |
Omacetaxine mepesuccinate |
| Original developer |
Cephalon |
| Commercial owner |
Teva Pharmaceutical Industries following its acquisition of Cephalon |
| FDA application |
NDA 203585 |
| U.S. approval |
October 2012 |
| Approved indication |
Adults with chronic-phase or accelerated-phase CML resistant or intolerant to at least two TKIs |
| Administration |
Subcutaneous injection |
| Initial treatment schedule |
Twice daily for 14 consecutive days in a 28-day cycle |
| Maintenance schedule |
Twice daily for 7 consecutive days in a 28-day cycle |
| FDA pathway |
Accelerated approval |
| Key clinical limitation |
Myelosuppression, injection burden, and narrow treatment positioning |
The FDA approval relied on response data from a single-arm clinical program rather than a randomized comparative trial. The label reported major cytogenetic response rates of approximately 18% in chronic-phase CML and 14% in accelerated-phase CML populations with substantial prior treatment exposure (FDA, 2012).
When did SYNRIBO lose exclusivity?
SYNRIBO’s regulatory exclusivity was short relative to the lifecycle of large oncology products. The FDA granted orphan-drug designation, which generally provides seven years of U.S. market exclusivity from approval, subject to statutory exceptions. For an approval dated October 26, 2012, the principal orphan exclusivity period would have extended to October 2019.
| Exclusivity element |
Estimated or reported timing |
| FDA approval |
October 26, 2012 |
| Orphan-drug exclusivity |
Through approximately October 26, 2019 |
| Accelerated-approval basis |
Single-arm response data |
| Post-approval obligation |
Confirmatory evidence requirement |
| Standalone revenue disclosure |
Not provided in Teva public filings |
Orphan exclusivity did not guarantee commercial success. The eligible patient population was small, and SYNRIBO competed against an expanding sequence of oral TKIs. The product also had a more difficult administration profile than oral alternatives.
A later generic or biosimilar-style challenge was not the central commercial threat. SYNRIBO is a small-molecule drug, so the relevant competitive pathway is abbreviated new drug approval rather than biosimilar approval. Publicly visible market pressure came primarily from branded and generic TKIs, treatment sequencing, and the declining use of omacetaxine in routine CML care.
What patents protect SYNRIBO?
SYNRIBO’s protection was based on patents covering omacetaxine compositions, pharmaceutical formulations, treatment methods, and related uses. The precise commercial impact of these patents depends on claim scope, terminal disclaimers, patent-term adjustment, Orange Book listings, and any Paragraph IV certifications.
The public commercial record does not establish a broad, durable patent moat comparable to that of leading CML TKIs. The most important protection was the combination of orphan-drug exclusivity, regulatory approval, manufacturing know-how, and a specialized hematology distribution channel.
Does SYNRIBO have Orange Book-listed patents?
SYNRIBO was approved under FDA NDA 203585. Orange Book patent coverage can change as patents expire, delist, or become subject to regulatory updates. The Orange Book remains the controlling source for current listed patents and pediatric exclusivity. Publicly available commercial evidence does not indicate that a major wave of Paragraph IV litigation materially altered SYNRIBO’s sales trajectory.
For market analysis, the relevant distinction is:
- SYNRIBO had a small, specialized market even while exclusivity remained in force.
- Loss of orphan exclusivity did not automatically create substantial generic demand.
- A generic entrant would have faced a limited market, difficult injectable manufacturing, and a treatment population already concentrated in highly specialized centers.
- TKI substitution was a more important competitive factor than a direct omacetaxine generic launch.
What was the FDA regulatory status of SYNRIBO?
SYNRIBO received accelerated approval in 2012 for patients with treatment-resistant or treatment-intolerant CML. Accelerated approval allowed commercialization based on an intermediate endpoint, with confirmatory evidence required after launch.
The product label required close monitoring because of severe and potentially fatal hematologic toxicity. Common and clinically important adverse effects included thrombocytopenia, neutropenia, anemia, febrile neutropenia, infection, hyperglycemia, nausea, diarrhea, and injection-site reactions.
Its regulatory positioning created two commercial constraints:
- Treatment was reserved for a late-line population.
- The administration schedule created a higher burden than oral TKIs.
The FDA indication was narrower than the broader CML market. By the time patients reached the SYNRIBO treatment line, many had access to newer TKIs, mutation-directed treatment, allogeneic stem-cell transplantation, or clinical trials.
How did SYNRIBO compete with CML drugs?
SYNRIBO entered a market dominated by BCR-ABL TKIs. These drugs had stronger physician familiarity, oral administration, deeper molecular-response data, and broader use across treatment lines.
| Drug or class |
Principal commercial advantage over SYNRIBO |
Principal limitation |
| Imatinib |
Low cost, extensive clinical history, generic availability |
Resistance and intolerance in later-line patients |
| Dasatinib |
Potent activity and broad CML use |
Pleural effusion and other tolerability concerns |
| Nilotinib |
Strong molecular-response performance |
Cardiovascular and metabolic safety monitoring |
| Bosutinib |
Later-line use and oral administration |
Gastrointestinal and hepatic adverse effects |
| Ponatinib |
Activity against T315I mutation |
Vascular safety risks and restricted use |
| Asciminib |
Allosteric BCR-ABL inhibition and later-line positioning |
Newer-product access, price, and evolving treatment sequencing |
| SYNRIBO |
Non-TKI mechanism and activity after TKI failure |
Injection burden, myelosuppression, and narrow use |
The arrival of asciminib further weakened the strategic position of omacetaxine in resistant CML. Asciminib offered an oral, targeted alternative for patients previously treated with multiple TKIs, including patients with the T315I mutation in applicable settings (FDA, 2021).
What were SYNRIBO’s sales and financial trajectory?
Teva did not report SYNRIBO as a separate revenue line in its principal annual reports. The product was grouped within broader specialty, innovative, or other pharmaceutical categories. That reporting structure prevents a reliable public calculation of annual SYNRIBO sales, gross margin, or product-level profitability.
The commercial trajectory can nevertheless be mapped:
| Period |
Market event |
Financial implication |
| 2012-2013 |
FDA approval and launch |
Initial specialty-oncology investment and market-building costs |
| 2014-2016 |
Limited adoption in later-line CML |
Revenue remained constrained by small eligible population |
| 2017-2019 |
Continued TKI competition and growing treatment alternatives |
Weak growth potential and pressure on prescribing |
| Around 2019 |
Expiration of primary orphan exclusivity period |
Greater theoretical entry risk, although direct generic competition was limited |
| 2020 onward |
Portfolio rationalization and reduced strategic relevance |
Product likely became a low-priority commercial asset |
Teva’s broader financial trajectory during this period was dominated by Copaxone erosion, debt reduction, generic-drug pricing pressure, restructuring, and the integration and optimization of acquired assets. SYNRIBO was too small to materially affect consolidated results. Its economic contribution was more likely measured through specialty portfolio fit, sales-force utilization, and manufacturing complexity than through material company-wide revenue.
Why were SYNRIBO sales structurally limited?
The main constraints were commercial rather than purely legal:
- The indication applied only after resistance or intolerance to at least two TKIs.
- CML treatment had shifted toward deep molecular response and long-term oral therapy.
- Omacetaxine required repeated subcutaneous administration.
- Myelosuppression required blood-count monitoring and dose interruptions.
- The drug had no broad solid-tumor indication.
- Competing TKIs were available in generic and branded forms.
- The late-line CML population was fragmented across academic and specialty practices.
- Treatment guidelines generally positioned omacetaxine as an option after multiple prior therapies, not as a preferred earlier-line treatment.
Which companies challenged SYNRIBO?
No major public litigation campaign against SYNRIBO is associated with the product’s commercial history. Publicly visible competitive pressure came from manufacturers of alternative CML therapies rather than from a prominent direct generic entrant.
The principal competitive companies included:
- Novartis, with imatinib and nilotinib
- Bristol Myers Squibb, with dasatinib
- Pfizer, with bosutinib
- Takeda, with broader oncology and hematology offerings
- Ariad Pharmaceuticals, later integrated into Takeda, with ponatinib
- Novartis, with asciminib
The competitive landscape reduced SYNRIBO’s addressable market even without a successful Paragraph IV challenge. In specialty oncology, a drug can lose commercial relevance when physicians have better tolerated, easier-to-administer, or more targeted alternatives.
What patent litigation and settlement agreements affected SYNRIBO?
There is no widely reported SYNRIBO patent settlement that materially shaped the product’s market entry or revenue curve. The absence of major litigation is consistent with the product’s limited sales potential and the commercial difficulty of launching a competing injectable treatment into a small late-line population.
A generic applicant would have needed to address:
- Active-ingredient and formulation patents
- Orange Book certifications
- Injectable manufacturing controls
- Sterility and stability requirements
- Restricted market size
- Physician familiarity with alternative therapies
- Potential need for specialized oncology distribution
These factors reduced the expected value of a direct generic challenge. They also limited the probability that patent expiry alone would produce a substantial price collapse comparable to a high-volume oral medicine.
What manufacturing and intellectual-property barriers affect SYNRIBO?
Omacetaxine is derived from homoharringtonine, a cephalotaxine alkaloid. Production requires control of active pharmaceutical ingredient quality, formulation stability, sterile injectable processing, and dose uniformity.
The manufacturing profile creates a higher barrier than a standard oral tablet:
- Sterile fill-finish capacity is required.
- Small batch sizes can create unfavorable unit economics.
- Oncology injectable manufacturing requires validated contamination controls.
- Supply interruptions can affect a concentrated patient population.
- A generic manufacturer must justify product sameness through an abbreviated approval pathway.
These barriers do not create permanent protection. They raise the cost and reduce the expected return of entry into a low-volume market.
What is the outlook for SYNRIBO revenue and generic entry?
SYNRIBO’s long-term revenue outlook is limited. The product’s commercial base depends on a narrow group of multiply treated CML patients and on continued use after newer TKIs and mutation-directed therapies have been considered.
The most likely market scenarios are:
| Scenario |
Market outcome |
| Continued niche use |
Low, stable demand in selected heavily pretreated patients |
| Direct generic entry |
Price erosion, but limited absolute market impact because the treated population is small |
| Product withdrawal or delisting |
Conversion of remaining patients to alternative TKIs or clinical options |
| New clinical evidence |
Unlikely to materially expand use without a differentiated indication |
| Manufacturing disruption |
Potential short-term shortages because of limited suppliers and specialized production |
The main investment conclusion is that SYNRIBO is not a material revenue-exposure asset for Teva. Its strategic value lies in residual specialty access and treatment-option breadth, not in growth, pricing power, or durable market expansion.
How strong is the SYNRIBO patent estate?
SYNRIBO’s effective protection was moderate to weak from a commercial perspective. Orphan exclusivity provided a defined period without approved competing products for the same orphan indication, but the underlying market was too small to support major sales. Patent protection and manufacturing know-how added barriers, yet neither solved the product’s central commercial problems: limited eligibility, dosing burden, and competition from oral TKIs.
The asset’s strongest protection was regulatory positioning in a highly specialized indication. Its weakest element was market scale.
Key Takeaways
- SYNRIBO is omacetaxine mepesuccinate, a subcutaneous treatment for multiply treated CML.
- Teva acquired the product through its acquisition of Cephalon.
- FDA approval occurred in October 2012 under the accelerated-approval pathway.
- Orphan exclusivity likely ran through approximately October 2019.
- Teva did not disclose standalone SYNRIBO sales in its major public filings.
- The product’s market was constrained by late-line positioning, injection burden, myelosuppression, and competition from TKIs.
- Generic entry was less important than therapeutic substitution by oral targeted drugs.
- No major public Paragraph IV campaign or patent settlement is known to have driven the product’s market trajectory.
- SYNRIBO was unlikely to represent material consolidated revenue for Teva.
- Long-term demand is limited to selected patients with advanced treatment-resistant CML.
FAQs About SYNRIBO Market and Patent Risk
Is SYNRIBO still commercially available?
Availability has depended on market and period. Public company filings do not identify a current standalone commercial business for SYNRIBO, and the product has had limited strategic visibility within Teva’s portfolio.
Is omacetaxine a generic drug?
Omacetaxine is the generic name for the active ingredient in SYNRIBO. That does not establish the existence of an approved generic omacetaxine product. Generic availability requires a separate abbreviated new drug application and FDA approval.
Does SYNRIBO have biosimilar competition?
No. SYNRIBO is a small-molecule drug, not a biologic. Any follow-on product would proceed through the generic-drug pathway rather than the biosimilar pathway.
What replaced SYNRIBO in resistant CML?
Treatment options include later-generation TKIs, ponatinib, asciminib, allogeneic stem-cell transplantation in suitable patients, and clinical trials. The appropriate choice depends on mutation status, prior treatment, disease phase, cardiovascular risk, and treatment response.
Did SYNRIBO become a major Teva product?
No. Teva’s public financial reporting did not identify SYNRIBO as a major standalone revenue contributor. Its commercial role was that of a niche specialty-oncology product.
References
- U.S. Food and Drug Administration. (2012). SYNRIBO (omacetaxine mepesuccinate) prescribing information.
- U.S. Food and Drug Administration. (2021). SCEMBLIX (asciminib) prescribing information.
- Teva Pharmaceutical Industries Ltd. (2012). Annual report for the year ended December 31, 2012.
- Teva Pharmaceutical Industries Ltd. (2019). Annual report for the year ended December 31, 2019.
- Teva Pharmaceutical Industries Ltd. (2020). Annual report for the year ended December 31, 2020.
- National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
